Navigation Links
Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results

Operating Loss Continues to Decline; Strategic Business Unit Realignment Completed; Clinical Update Provided for NicVAX Phase 2b Proof of Concept


BOCA RATON, Fla., Aug. 1 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced its second quarter financial results. The company recorded a net loss from continuing operations of $5.3 million, or $0.09 per share, for the quarter ended June 30, 2007, compared to $13.7 million, or $0.22 per share for the quarter ended July 1, 2006. Revenues for the second quarter of 2007 were $20.9 million compared to $20.4 million in 2006. Nabi-HB(R) [Hepatitis B Immune Globulin (Human)] revenues were $8.7 million during the second quarter of 2007 compared to $7.2 million during the second quarter of 2006.

For the six months ended June 30, 2007, the company's net loss from continuing operations was $16.0 million, or $0.26 per share, compared to $29.1 million, or $0.48 per share, for the six months ended July 1, 2006. Revenues for the year to date period were $44.6 million compared to $39.9 million in the first half of 2006.

Total cash used in operating activities was $18.9 million during the first half of 2007, a 44% reduction compared to $33.7 million in the first half of 2006. Excluding discontinued operations, cash used in operating activities was $13.1 million for the first half of 2007, a 53% reduction compared to $27.7 million for six months ended July 1, 2006. Cash, cash equivalents and marketable securities were $103.9 million at the end of the second quarter.

Nabi has completed the formation of two strategic business units (SBUs) -- Nabi Biologics and Nabi Pharmaceuticals -- to realign and >

Revenues $ 20,873 $ 20,374 $ 44,621 $ 39,891

Cost of products sold 11,680 14,366 26,487 28,882

Gross margin 9,193 6,008 18,134 11,009

Selling, general and

administrative expense 8,574 11,143 18,587 22,999

Research and development

expense 9,048 8,883 19,104 17,661

Operating loss (8,429) (14,018) (19,557) (29,651)

Interest income 1,419 945 2,999 2,008

Interest expense (886) (905) (1,803) (1,858)

Other income, net 2,561 317 2,559 382

Loss from continuing

operations before

income taxes (5,335) (13,661) (15,802) (29,119)

Income taxes - - (190) -

Loss from continuing

operations (5,335) (13,661) (15,992) (29,119)

Net income (loss) from

discontinued operations 557 (1,163) 185 (3,782)

Net loss $ (4,778) $ (14,824) $ (15,807) $ (32,901)

Basic and diluted (loss)

income per share:

Continuing operations $ (0.09) $ (0.22) $ (0.26) $ (0.48)

Discontinued operations 0.01 (0.02) 0.00 (0.06)

Basic and diluted loss

per share (0.08) (0.24) (0.26) (0.54)

Basic and diluted

weighted average shares

outstanding 61,280 60,977 61,192 60,653

Nabi Biopharmaceuticals



(in thousands)

For the Six Months Ended

June 30, July 1,

2007 2006

Cash flow from operating activities:

Loss from continuing operations $ (15,992) $ (29,119)

Adjustments to reconcile loss

from continuing operations to net

cash used in operating activities

from continuing operations:

Depreciation and amortization 4,150 4,464

Provision for slow moving or

obsolete inventory 111 453

Non-cash compensation 1,515 1,789

Gain on sale of assets, net (2,557) -

Disposal of fixed assets, net 40 236

Other 96 (407)

Changes in assets and liabilities:

Trade accounts receivable 3,875 4,277

Inventories (85) (2,097)

Prepaid expenses and other

current assets (634) (100)

Other assets 15 80

Accounts payable and accrued

expenses (3,589) (7,257)

Total adjustments 2,937 1,438

Net cash used in operating activities

from continuing operations (13,055) (27,681)

Net cash used in operating activities

from discontinued operations (5,803) (5,990)

Net cash used in operating activities (18,858) (33,671)

Cash flow from investing activities:

Purchases of marketable securities (28,500) (63,475)

Proceeds from sales of marketable

securities 25,575 29,550

Proceeds from sale of assets,

net of closing costs 1,300 8

Capital expenditures (568) (1,059)

Net cash used in investing activities

from continuing operations (2,193) (34,976)

Net cash provided by investing

activities from discontinued

operations 2,582 -

Net cash provided by (used in) investing

activities 389 (34,976)

Cash flow from financing activities:

Repayments of notes payable and

capital leases (137) (72)

Proceeds from exercise of employee

stock options 604 1,137

Net cash provided by financing activities

from continuing operations 467 1,065

Net cash provided by (used in) financing

activities from discontinued operations 292 (3,059)

Net cash provided by (used in) financing

activities 759 (1,994)

Net decrease in cash and cash equivalents (17,710) (70,641)

Cash and cash equivalents at beginning

of period 86,227 101,762

Cash and cash equivalents at end

of period $ 68,517 $ 31,121

Nabi Biopharmaceuticals


(Unaudited, in thousands)

For the Three For the Six

Months Ended Months Ended

June 30, July 1, June 30, July 1,

2007 2006 2007 2006


Nabi Biologics $ 20,847 $ 19,876 $ 44,614 $ 38,927

Nabi Pharmaceuticals 26 498 7 964

Total $ 20,873 $ 20,374 $ 44,621 $ 39,891

Gross margin (loss):

Nabi Biologics $ 9,192 $ 5,649 $ 18,245 $ 10,606

Nabi Pharmaceuticals 1 359 (111) 403

Total $ 9,193 $ 6,008 $ 18,134 $ 11,009

Operating income (loss):

Nabi Biologics $ 1,086 $ 155 $ 3,438 $ 693

Nabi Pharmaceuticals (2,809) (5,798) (7,735) (13,466)

Segment operating loss (1,723) (5,643) (4,297) (12,773)

CSS (6,706) (8,375) (15,260) (16,878)

Total $ (8,429) $ (14,018) $ (19,557) $ (29,651)

optimize our businesses and support the strategic alternatives process. In connection with this realignment, the company also created a Corporate Shared Services (CSS) group. Given the creation of these two SBUs and the CSS group, Nabi has revised its segment reporting disclosures. Second quarter operating results for these segments were:

-- Nabi Biologics revenues were $20.8 million in the second quarter of

2007, which included $11.9 million and $8.7 million in sales of

antibody and Nabi-HB products, respectively. Nabi Biologics operated

as a profitable SBU, with an operating income of $1.1 million for the

three months ended June 30, 2007.

-- The Nabi Pharmaceuticals SBU posted an operating loss of $2.8 million

in the second quarter of 2007 driven by its research and development

costs, which were strategically reduced by 56% from $6.4 million

during the same quarter in 2006.

-- Corporate Shared Services costs totaled $6.7 million for the three

months ended June 30, 2007, a 20% reduction from the second quarter of


"We are pleased to see the stand-alone performance of the Nabi Biologics SBU and continue our efforts to strengthen and advance the Biologics pipeline," said Dr. Leslie Hudson, interim president and chief executive officer of Nabi Biopharmaceuticals. "We have also taken critical steps to move Nabi Pharmaceuticals - and its key programs, NicVAX and StaphVAX - closer to a strategic partnership and to the market. We are very optimistic about the clinical benefit of NicVAX, as evidenced by our continuing flow of positive data from our NicVAX Phase 2b trial."

NicVAX Phase 2b Clinical Trial Update

Nabi also announced today initial nine-month findings from its ongoing trial of NicVAX(R) (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse:

-- Further analysis of the six-month data has enabled Nabi to determine

both the therapeutic threshold at which quitting is first observed as

well as the target upper limit of antibody concentration.

-- In the nine-month data, NicVAX continues to demonstrate efficacy in

support of long-term smoking abstinence - the most effective NicVAX

dose regimen was 400 micrograms delivered in five injections over six

months. A statistically significant difference was seen when this

treated group was compared to placebo over time for the full Intent to

Treat (ITT) population:

-- Fixed 4-Week: NicVAX=24% (n=12/51); Placebo=14% (n=14/100) - p=0.14

-- Fixed 8-Week: NicVAX=20% (n=10/51); Placebo=13% (n=13/100) - p=0.29

-- Fixed 20-Week: NicVAX=20% (n=10/51); Placebo= 4% (n=4/100) -


-- Fixed 34-Week: NicVAX=18% (n=9/51); Placebo=4% (n=4/100) - p=0.0047

-- To date, NicVAX continues its attractive safety trends with a

favorable adverse events profile comparable between placebo and each

dose group.

Recent Accomplishments


-- Executed a definitive agreement to sell Aloprim(TM) (allopurinol

sodium) for Injection to Bioniche Teoranta for $3.7 million; the sale

was completed in May


-- Established "proof of concept" for NicVAX in its Phase 2b clinical

trial, which met its primary endpoint of eight weeks of continuous

smoking abstinence between weeks 19-26

-- Participated in the Phacilitate Vaccine Forum Munich 2007, where

NicVAX principal investigator Dr. Dorothy Hatsukami, Forster Family

Professor in Cancer Prevention and Professor of Psychiatry at the

University of Minnesota Tobacco Use Research Center, discussed NicVAX

Phase 2b data in greater detail


-- Formed the Nabi Biologics SBU and expanded the role of Dr. Raafat

Fahim, Senior Vice President, Research, Technical and Production

Operations to also include Chief Operating Officer and General Manager

of the Biologics SBU

-- Formed the Corporate Shared Services (CSS) group and expanded the role

of Jordan Siegel to Senior Vice President, Finance and Administration,

Chief Financial Officer and Treasurer


-- Formed the Nabi Pharmaceuticals SBU and appointed Dr. Matthew W.

Kalnik Vice President, Business Development and Project Management to

accelerate partnership discussions for Nabi's NicVAX and StaphVAX


-- Reorganized the Nabi employee base to better align with the new

internal structure -- Nabi has eliminated a total of 65 positions and

expects to realize future annualized savings of approximately $6.3


-- Completed enrollment in our Anti-D Phase I trial; study completion

expected by end of 2007

Upcoming Milestones

Nabi is currently working toward achieving the following corporate milestones in 2007:

-- Successfully complete the strategic alternatives process with the

support of Banc of America Securities LLC

-- Continue to work to obtain approval for Nabi-HB(R) Intravenous

[Hepatitis B Immune Globulin (Human) Intravenous] in the U.S.;

leverage expertise of Cato Research Ltd.

-- Advance development partnerships for NicVAX and the Gram-positive


-- Continue to provide data from Nabi's ongoing Phase 2b trial of NicVAX

-- Complete enrollment in the 'proof of concept' clinical trial for


-- Resubmit the file for regulatory approval of HEBIG(TM) [Hepatitis B

Immune Globulin (Human) Intravenous] in Europe

-- Continue patient recruitment in the Phase 3 trial of ATG-Fresenius S

(anti-T-lymphocyte globulin) in lung transplant patients

-- Initiate the clinical trial of our intravenous immunoglobulin, IVIG

Review of Operations

Nabi Biologics

Nabi Biologics revenues were $20.8 million in the second quarter of 2007, which primarily included $11.9 million and $8.7 million in sales of antibody and Nabi-HB products, respectively. This was an increase of $1.0 million from the second quarter of the prior year due to increased end user demand and sales of Nabi-HB.

Nabi Biologics research and development expenses totaled $6.2 million during the three months ended June 30, 2007, compared to $2.5 million for the same period last year, due largely to acceleration of Nabi's Civacir, Anti-D and IVIG clinical development programs.

Nabi Pharmaceuticals

Nabi Pharmaceuticals research and development costs were $2.8 million during the three months ended June 30, 2007, compared to $6.4 million for the same period last year. This is largely the result of decreased spending associated with StaphVAX and a $0.9 million benefit related to NicVAX from our grant by the U.S. National Institute on Drug Abuse.

Corporate Shared Services

CSS costs included those associated with finance, IT, HR, business development, legal, government affairs, investor relations, corporate governance and executive administration activities and totaled $6.7 million for the three months ending June 30, 2007, compared to $8.4 million for the second quarter in 2006. This decrease reflects lower consulting and personnel-related expenses incurred in the current year quarter as we reorganized our internal employee base and continue to lower our overall infrastructure costs.

Second Quarter Financial Results Conference Call

The company will host a live webcast at 4:30 p.m. EDT today to discuss these results.

The live webcast can be accessed at: eventDetails&c=100445&eventID=1603855 or via the Nabi Biopharmaceuticals website at

If you do not have Internet access, the U.S./Canada call-in number is (800) 638-5439, conference code 14030912, and the international call-in number is (617) 614-3945, conference code 14030912. An audio replay will be available for U.S./Canada callers at (888) 286-8010, conference code 74258104, and for international callers at (617) 801-6888, conference code 74258104.

An archived version of the webcast will be available at the same Internet address through August 8, 2007. The audio replay also will be available through August 8, 2007. The press release will be available on the company's website at

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and, in certain areas, market products that target serious medical conditions in the areas of hepatitis and transplants, gram positive bacterial infections and nicotine addiction. We are a vertically integrated company with sales of antibodies and other biologics, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], a pipeline of products in various stages of development, state-of-the-art manufacturing capability and a cash position that will allow us to advance our near-term pipeline products. The company has recently announced the formation of two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics has responsibility for the company's protein and immunological products and development pipeline, including Nabi-HB. Nabi Pharmaceuticals is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs. For a complete list of pipeline products, please go to: The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site:

Forward-Looking Statements

Statements in this release that are not strictly historical are forward- looking statements and include statements about reorganization of our current business into two new business units, our strategic alternatives process and clinical trials and studies. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward- looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to: realize anticipated cost savings related to job elimination due to greater than anticipated severance-related costs or other factors; successfully partner with third parties to fund, develop, manufacture and/or distribute our existing and pipeline products, including NicVAX and our Gram- positive infections products; obtain successful clinical trial results; our ability to successfully complete our strategic alternatives process; generate sufficient cash flow from sales of products or from milestone or royalty payments to fund our development and commercialization activities; attract and maintain the human and financial resources to commercialize current products and bring to market products in development; depend upon third parties to manufacture or fill our products; achieve approval and market acceptance of our products; expand our sales and marketing capabilities or enter into and maintain arrangements with third parties to market and sell our products; effectively and/or profitability use, or utilize the full capacity of, our vaccine manufacturing facility; manufacture NicVAX or other products in our own vaccine manufacturing facility; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and our Quarterly Report for the quarter ended March 31, 2007 on Form 10-Q with the Securities and Exchange Commission.

Nabi Biopharmaceuticals



(In thousands)

June 30, December 30,

2007 2006


Current assets:

Cash and cash equivalent $ 68,517 $ 86,227

Marketable securities 35,425 32,500

Trade accounts receivable, net 16,489 20,377

Inventories, net 18,592 19,260

Prepaid expenses and other

current assets 5,483 3,459

Assets of discontinued

operations 338 13,341

Total current assets 144,844 175,164

Property, plant and equipment, net 84,816 88,329

Other assets:

Intangible assets, net 1,247 1,683

Other, net 1,523 701

Total assets $232,430 $265,877

Liabilities and stockholders' equity

Current liabilities:

Trade accounts payable $ 6,751 $ 7,998

Accrued expenses 14,106 16,095

Capital lease obligations, net 155 291

Liabilities of discontinued

operations 4,146 20,554

Total current liabilities 25,158 44,938

2.875% convertible senior notes,

net 109,397 109,313

Other liabilities 243 238

Total liabilities 134,798 154,489

Commitments and contingencies

Stockholders' equity:

Convertible preferred stock - -

Common stock 6,190 6,149

Capital in excess of par 329,237 327,228

Treasury stock (5,321) (5,321)

Accumulated deficit (232,474) (216,668)

Total stockholders' equity 97,632 111,388

Total liabilities and

stockholders' equity $ 232,430 $ 265,877

Nabi Biopharmaceuticals



(In thousands, except per share amounts)

For the Three For the Six

Months Ended Months Ended

June 30, July 1, June 30, July 1,

2007 2006 2007 2006 '/>"/>

SOURCE Nabi Biopharmaceuticals

Copyright©2007 PR Newswire.

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Sygnis Pharma AG announces date for presentation of clinical results
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):